
DNAtrix Inc Profile last edited on: 9/23/2020
CAGE: 5JY93
UEI: N5SVUABKNRB8
Business Identifier: Targeted oncolytic virus therapies for treating malignant glioma Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2450 Holcombe Boulevard Suite X+ 200
Houston, TX 77021
Houston, TX 77021
(832) 930-2401 |
info@dnatrix.com |
www.dnatrix.com |
Location: Single
Congr. District: 18
County: Harris
Congr. District: 18
County: Harris
Public Profile
DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. An Alumni of the JLabs SanDiego. and having very limited SBIR Involvement, in 2012 DNAtrix had merged/acquired another SBIR firm, Vectorlogics of Birmingham, AL. Viruses are understood to be good at killing cells. Hence scientists have harnessed this ability by modifying a common cold virus so that it targets and kills cancer cells selectively. The Companys lead product, DNX-2401, had been the culmination of more than a decade of scientific and clinical research and proved to be the most potent and effective oncolytic virus delivered to human brain tumors to that point. DNAtrix's oncolytic viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNAtrix has multiple virus candidates in clinical trials for cancers with urgent need for novel approaches. DNAtrixs oncolytic viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNAtrix has multiple virus candidates in clinical trials for cancers with urgent need for novel approaches.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 2 | NIH | $852,569 | |
Project Title: Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569 | ||||
2014 | 1 | NIH | $160,632 | |
Project Title: Ex Vivo Purging Strategy for Treatment of Multiple Myeloma |
Key People / Management
Frank Tufaro -- Former Chief Executive Officer
Charles Conrad -- Co-Founder
Brett Ewald -- Vice President, Development
Juan Fueyo -- Co-Founder
Cande Manzano -- Co-Founder
Grant Mcfadden -- Advisor
Joan Marie Robbins
Al Yung -- Founder
Charles Conrad -- Co-Founder
Brett Ewald -- Vice President, Development
Juan Fueyo -- Co-Founder
Cande Manzano -- Co-Founder
Grant Mcfadden -- Advisor
Joan Marie Robbins
Al Yung -- Founder